Establishment method and application of systemic amyloidosis model
By injecting amyloid lysozyme LYSO-6 in mice, a systematic amyloidosis model was established, which solved the problem of difficulty in simulating multi-organ amyloidosis in the prior art, and achieved effective use in drug screening and research Model.
Patent Information
- Application Number
- CN202410860291.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-04
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-04
AI Technical Summary
The prior art has not yet provided an effective systemic amyloid biological model, and it is difficult to simulate and study the secondary pathological status of amyloid in multiple organs and cells.
Systemic amyloidosis model was established by stimulating inflammation in mice and injecting amyloid lysozyme LYSO-6 in the tail vein, including lesions of the heart, liver, spleen, kidney, blood vessels and skin tissues, and simulated amyloidosis in vivo. Pathological status.
A systemic amyloid mouse model was successfully established to screen and study the treatment and prevention drugs for amyloidosis, with good application prospects.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular, relates to a method for establishing a systemic amyloidosis model and its application. Background Art
[0002] Amyloidosis is a chronic clinical syndrome caused by multiple factors that causes the misfolding of amyloid precursor protein and its gradual aggregation to form insoluble fibers, which are deposited between tissues and organs of the human body and gradually cause their functions to fail. The disease can be divided into systemic (multiple organ involvement) and localized (only one organ is involved) according to the site of the lesion.
[0003] Kidney is an important place for metabolism of many substances, and it is also one of the organs where amyloidosis most often occurs and is affected. Renal amyloidosis is more common in middle-aged and elderly patients, with the main clinical manifestations of proteinuria or nephrotic syndrome, which may eventually develop into end-stage renal disease. Among them, the protein-rich mesangial area of the glomerulus is the most vulnerable site for amyloid deposition. The mesangial area is composed of mesangial cells and the mesangial matrix they produce, and has multiple functions such as support, contraction, phagocytosis, and secretion. The earliest manifestations of glomerular amyloidosis are mesangial cell damage and mesangial matrix thickening. Amyloid deposits can be seen in the glomerular mesangial area by light microscopy and electron microscopy.
[0004] Hepatic amyloidosis is caused by the accumulation of misfolded proteins in the liver, which leads to a series of liver damages such as inflammatory infiltration of hepatocytes and tissues and subsequent liver failure. Amyloid A (AA) is an acute phase reactant produced by the liver, and serum amyloid A (SAA) is its precursor. SAA is a typical amyloid protein in the liver and plays a key role in the initiation and maintenance of inflammation. SAA induces neutrophilia at the site of inflammation and induces the secretion of multiple inflammatory cytokines, including TNF-α, IL-6, etc. Alterations in SAA expression play a pathogenic role in the deposition of hepatic amyloid. Sustained increase of SAA is a prerequisite for the occurrence of hepatic amyloidosis.
[0005] In addition to the most common amyloidosis of the liver and kidney, the heart, spleen, blood vessels and skin are also organs or tissues prone to systemic amyloid lesions. The deposition of amyloid protein in cardiac tissue can cause left ventricular hypertrophy, impaired cardiac relaxation and increased ventricular stiffness, leading to cardiac systolic dysfunction. When the disease progresses to the end stage, the patient's left ventricular ejection fraction decreases significantly, manifesting as heart failure. In the spleen, amyloid protein often deposits in the splenic white pulp and blood vessels, leading to splenomegaly and calcification. Splenic amyloidosis is usually a benign lesion in the early stage, and long-term development will increase the risk of splenic bleeding and rupture.
[0006] Egg white lysozyme is one of the most widely studied proteins for amyloidosis. It forms amyloid fibrils when incubated in vitro. In addition, egg white lysozyme is similar in structure to human lysozyme and has a high degree of homology, which makes it often used as a model protein for in vivo and in vitro studies of amyloidosis.
[0007] So far, there are no reports that amyloidogenic lysozyme (LYSO-6) can induce secondary systemic amyloidosis in multiple organs and cells in vivo or in vitro. Summary of the invention
[0008] The purpose of the present invention is to overcome the technical problems existing in the prior art, provide a method for establishing a systemic amyloidosis biological model, and simultaneously provide an application thereof.
[0009] To achieve the above object, the technical solution adopted by the present invention is: The first aspect of the present invention provides a method for establishing a systemic amyloidosis model. The mice are first stimulated with drugs to produce inflammation, during which amyloidosis lysozyme LYSO-6 is injected into the tail vein to obtain a systemic amyloidosis model.
[0010] As a further improvement of the present invention, the method of stimulating inflammation in mice is: administering 0.15-0.25 mL of 1.5-2.5% AgNO3 subcutaneously on the back for 13-15 consecutive days to stimulate inflammation.
[0011] As a further improvement of the present invention, 0.05-0.15 mL of amyloid lysozyme LYSO-6 with a final concentration of 0.5-1.5 mg / mL is injected through the tail vein on days 7-9 and 13-15, respectively.
[0012] As a further improvement of the present invention, the mice are selected from 7-week-old male C57BL / 6 mice.
[0013] As a further improvement of the present invention, the amyloid pathological tissue includes heart tissue, liver tissue, spleen tissue, kidney tissue, blood vessel and skin tissue.
[0014] As a further improvement of the present invention, the time for establishing the systemic amyloidosis model is 48-52 days.
[0015] As a further improvement of the present invention, the preparation method of amyloid lysozyme LYSO-6 is as follows: S1: Add appropriate amount of egg white lysozyme powder to hydrochloric acid solution with a pH of 2 to a final concentration of 1mM, and let it stand at 4℃ for 8-10h to fully dissolve. After it is completely dissolved, filter it with a 0.22-0.45μm filter membrane; S2: Place the lysozyme incubation solution in a constant temperature oscillator with the oscillator setting conditions at 65±2℃, 50 rpm, incubate continuously for 6 days, and store at 3~5℃.
[0016] As a further improvement of the present invention, 7-week-old male C57BL / 6 mice were adaptively raised for one week, and starting from the 8th day, 0.20 mL of 2% AgNO3 was subcutaneously administered to the back for 14 consecutive days to stimulate inflammation, and 0.10 mL of amyloid lysozyme LYSO-6 with a final concentration of 1 mg / mL was injected once through the tail vein on the 8th day and the 15th day respectively to obtain a systemic amyloidosis model, and the mouse tissues were collected on the 50th day.
[0017] The second aspect of the present invention provides a systemic amyloidosis model obtained by the method.
[0018] The third aspect of the present invention provides an application of a systemic amyloidosis model obtained by the method in screening drugs for treating or preventing amyloidosis.
[0019] The beneficial effects of adopting the above technical solution are: The present invention injects amyloidosis lysozyme into the tail vein of mice to induce amyloidosis in mouse tissues and organs, thereby obtaining a systemic amyloidosis model. The systemic amyloidosis model obtained by the present invention can simulate the pathological state of systemic amyloidosis in vivo, is used for the activity screening of amyloidosis prevention and treatment drugs, and has good application prospects in the treatment and prevention of amyloidosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The HE staining results of the heart organ tissue sections of the control group and the model group in Example 1 of the present invention; Figure 2 The Congo red staining results of the heart organ tissue sections of the control group and the model group in Example 1 of the present invention; Figure 3 The HE staining results of liver organ tissue sections of the control group and the model group in Example 1 of the present invention; Figure 4 The Congo red staining results of liver organ tissue sections of the control group and the model group in Example 1 of the present invention; Figure 5 The HE staining results of spleen organ tissue sections of the control group and the model group in Example 1 of the present invention; Figure 6 The Congo red staining results of spleen organ tissue sections of the control group and the model group in Example 1 of the present invention; Figure 7 The HE staining results of kidney organ tissue sections of the control group and the model group in Example 1 of the present invention; Figure 8 The Congo red staining results of kidney organ tissue sections of the control group and the model group in Example 1 of the present invention; Fig. 9 The HE staining results of blood vessel (abdominal aorta) sections of mice in the control group and model group in Example 1 of the present invention; A: normal group (200×); B: model group (200×); C: normal group (500×); D: model group (500×); Fig.10 These are the Congo red staining results of blood vessel (abdominal aorta) sections of mice in the control group and the model group in Example 1 of the present invention; A: normal group (bright field); B: model group (bright field); C: normal group (dark field); D: model group (dark field) (200×). DETAILED DESCRIPTION
[0021] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is clearly and completely described below in conjunction with specific embodiments. Unless otherwise specified, the reagents and methods used in this embodiment are conventional.
[0022] The PBS buffer used in this example was prepared as follows: 1.2 g of Na2HPO4 powder and 0.2 g of KH2PO4 powder were dissolved in ddH2O and the volume was adjusted to 1000 mL.
[0023] The preparation method of hydrochloric acid solution with a pH of 2 is as follows: Under the monitoring of a pH meter, adjust the pH of triple distilled water to 2.0 with concentrated hydrochloric acid.
[0024] The preparation method of 2% AgNO3 solution is as follows: dissolve 0.5g AgNO3 powder in 25mL distilled water and filter with a 0.22μm filter membrane before use.
[0025] Preparation Example 1 Preparation of amyloid lysozyme LYSO-6 LYSO incubation solution: Weigh an appropriate amount of LYSO powder and add it to a pH 2 hydrochloric acid solution. The final concentration is 1×10 -3 M, let it stand at 4℃ overnight to allow it to fully dissolve. After it is completely dissolved, filter it once with a 0.22μm filter membrane.
[0026] Preparation of amyloidogenic lysozyme LYSO-6: The LYSO incubation solution was placed in a constant temperature oscillator with the oscillator setting conditions at 65°C and 50 rpm. The incubation was continued for 6 days and the samples were stored at 4°C.
[0027] Example 1 Method for establishing a mouse animal model of secondary systemic amyloidosis 1. Experimental Methods 1. Construction of mouse animal model Seven-week-old male C57BL / 6 mice were adaptively fed for one week and randomly divided into two groups (n=4), namely the blank group and the model group. Starting from the 8th day, the model group was subcutaneously administered with 0.2 mL of 2% AgNO3 to stimulate inflammation for 14 consecutive days, and 0.1 mL of LYSO-6 with a final concentration of 1 mg / mL was injected through the tail vein on the 8th and 15th days respectively; the blank group was injected with an equal amount of carrier solvent through the tail vein. On the 50th day, the liver, kidney, spleen, heart, blood vessels and skin of the mice were collected.
[0028] 2. Histopathological observation (1) Preparation of paraffin sections Fixation and sampling: Each tissue was fixed in 4% paraformaldehyde fixative for 24 hours. After removal, the target tissue was smoothed with a scalpel.
[0029] Dehydration and wax immersion: Place the tissue in a dehydrator for alcohol gradient dehydration. The dehydration solvent and time settings are as follows: 75% ethanol solution dehydration for 4 hours, 85% ethanol solution dehydration for 2 hours, 90% ethanol solution dehydration for 2 hours, 95% ethanol solution dehydration for 1 hour, anhydrous ethanol I dehydration for 30 minutes, anhydrous ethanol II dehydration for 30 minutes, xylene I dehydration for 5-10 minutes, xylene II dehydration for 5-10 minutes, 65℃ melted paraffin I dehydration for 1 hour, 65℃ melted paraffin II dehydration for 1 hour, 65℃ melted paraffin III dehydration for 1 hour.
[0030] Paraffin embedding: embed the wax-soaked tissue in an embedding machine. Before the wax solidifies, take the tissue out of the dehydration box and put it into the embedding frame, cool it in a -20℃ freezer, and after the wax solidifies, take the wax block out of the embedding frame and trim it.
[0031] Sectioning: The tissue wax blocks were cut into 5 μm thick sections, which were dried in a 65°C oven for 6 h and stored in a 4°C refrigerator.
[0032] (2) Tissue HE staining Baking: Bake the slices in a 65°C oven for 2 h.
[0033] Dewaxing: Place the sections in xylene I and II for 15 min each, anhydrous ethanol for 10 min, 90% ethanol solution, 80% ethanol solution, and 70% ethanol solution for 5 min each, and distilled water for 5 min.
[0034] Hematoxylin staining: Immerse the dewaxed sections in hematoxylin staining solution for 3 minutes to stain the cell nuclei.
[0035] Water washing: Rinse the tissue sections in running water for 5 minutes to return to blue.
[0036] 1% hydrochloric acid ethanol differentiation: The slices were placed in 1% hydrochloric acid ethanol for differentiation for 30 seconds.
[0037] Washing: Rinse the differentiated slices in tap water for 10 minutes.
[0038] Eosin staining: Place the sections in eosin staining solution for 1 min to stain the cytoplasm.
[0039] Washing: Rinse the slices in tap water for 5 minutes.
[0040] Gradient ethanol dehydration: Place the sections in 70% ethanol solution, 80% ethanol solution, and 90% ethanol solution for 30 seconds each, and then place them in anhydrous ethanol I and anhydrous ethanol II for 2 minutes each.
[0041] Transparency: Place the dehydrated tissue sections in xylene I and xylene II for 3 minutes each.
[0042] Sealing: Take the slices out of xylene and add neutral resin glue for sealing.
[0043] The images were taken under a bright field microscope and image analysis was performed.
[0044] (3) Tissue Congo red (CR) staining Baking: Bake the slices in a 65°C oven for 2 h.
[0045] Dewaxing: Place the sections in xylene I and xylene II for 15 min each, anhydrous ethanol for 10 min, 90% ethanol solution, 80% ethanol solution, and 70% ethanol solution for 5 min each, and distilled water for 5 min.
[0046] Hematoxylin staining: Immerse the dewaxed sections in hematoxylin staining solution for 3 minutes to stain the cell nuclei.
[0047] Water washing: Rinse the tissue sections in running water for 5 minutes to return to blue.
[0048] 1% hydrochloric acid ethanol differentiation: The slices were placed in 1% hydrochloric acid ethanol for differentiation for 30 seconds.
[0049] Washing: Rinse the differentiated slices in tap water for 10 minutes.
[0050] CR staining: After nuclear staining, the sections were immersed in CR staining solution and stained in the dark for 4 hours.
[0051] Washing: Rinse the tissue sections after CR staining with running tap water for 4 minutes to remove the dye floating on the surface.
[0052] Alkaline ethanol differentiation: Place the slices in alkaline ethanol differentiation solution for 10 seconds.
[0053] Gradient ethanol dehydration: Place tissue sections in 70% ethanol solution, 80% ethanol solution, and 90% ethanol solution for 30 seconds each, and then place them in anhydrous ethanol I and anhydrous ethanol II for 2 minutes each for dehydration.
[0054] Transparency: After dehydration, the tissue sections were placed in xylene I and xylene II for 3 minutes each to make them transparent.
[0055] Sealing: Take out the transparent slices from xylene and add neutral resin glue for sealing.
[0056] The images were taken under a polarizing microscope and analyzed.
[0057] 2. Experimental Results 1. Mouse heart staining results (1) HE staining Figure 1 The staining results showed that the myocardial fibers in the blank group were arranged neatly and tightly, while the gaps between the myocardial fibers in the model group became larger and the arrangement was disordered. In HE staining, amyloid protein was deposited in the form of eosinophilic homogeneous and unstructured clumps. Under the light microscope, amyloid substances were observed to be attached to the vascular walls of the model group. Compared with the blank group, the vascular walls of the arterioles were significantly thickened and the lumen was narrowed.
[0058] (2) Congo red staining Figure 2 The staining results showed that the Congo red-stained sections of the model group mice's hearts had uniformly stained orange-red substances under light microscopy, and apple green birefringence light appeared under polarized microscopy, indicating that amyloid protein existed in the model group mice's hearts and was mainly deposited in the myocardial interstitium. No amyloid protein deposition was observed in the blank group hearts.
[0059] 2. Mouse liver staining results (1) HE staining Figure 3 The staining results showed that the cell morphology of the liver lobules in the blank group was normal, the cells around the central vein were arranged neatly, and showed hepatocyte cords arranged radially outward. Compared with the blank group, some hepatocytes in the model group were swollen and balloon-like, losing their normal hexagonal shape, and their cytoplasm was fine reticular, and their hepatocyte cords were disordered.
[0060] (2) Congo red staining Figure 4 The staining results showed that uniform red-stained lumps were visible in the central vein of the model group under light microscopy, and the substance showed apple green birefringence under polarized light microscopy, indicating that amyloid was mainly deposited in the central vein wall. No amyloid protein deposition was observed in the liver of the blank group.
[0061] 3. Mouse spleen staining results (1) HE staining Figure 5 The staining results showed that the marginal zone of the white pulp in the model group proliferated. Since lymphocytes mature in the marginal zone of the white pulp and then migrate to the center of the white pulp, the deposition of amyloid in the marginal zone will affect the development of lymphocytes there, so the central lymphocytes decrease and the small lymphocytes in the marginal zone increase. Compared with the blank group, the cell morphology of the white pulp in the model group was swollen and the cells were loose.
[0062] (2) Congo red staining Figure 6 The staining results showed that orange-red substances existed at the junction of the white pulp and red pulp of the spleen in the model group, and apple green birefringence light could be seen under polarized light, while no orange-red substances and apple green birefringence light were found in the spleen of the blank group.
[0063] 4. Mouse kidney staining results (1) HE staining Figure 7 The staining results showed that the glomerular cells in the blank group were full and normal in morphology, the capillary cavities were open, and there was no deposition or proliferation in the mesangial area. Compared with the blank group, amyloid substances were present in the glomerular vascular plexus of the model group, the glomeruli were ischemic and shrunken, and capillary adhesion, closure and mesangial proliferation were observed.
[0064] (2) Congo red staining Figure 8 The staining results showed that amyloid protein was mainly deposited in the glomerular mesangial area and capillary wall. Under ordinary optical microscope, the glomerulus was stained dark red-brown, and under polarized light, the glomerulus showed apple green birefringence. The above phenomenon was not observed in the kidneys of the blank group.
[0065] 5. Mouse blood vessel (abdominal aorta) staining results (1) HE staining Fig. 9 HE staining results of the abdominal aorta of mice showed that the wall of the abdominal aorta in the blank control group was intact, and the elastic fibers were neat and wavy; in the model group, the elastic fibers became disordered and broken in some places.
[0066] (2) Congo red staining Fig.10 The staining results showed that after the abdominal aorta was stained with Congo red, the elastic fibers were orange-red and the amyloid fibers were reddish-brown. The elastic fibers in the control group were intact and showed a beautiful wavy shape; the elastic fibers in the model group were broken, the overall structure became disordered, and deposited reddish-brown substances could be seen locally. In the control group, apple green birefringence light was basically not seen under polarized light, while yellow-green birefringence light could be clearly seen in the gaps between the tube walls of the model group, which indicated that amyloid fibers were deposited in the model group.
[0067] 3. Experimental Conclusion By performing HE staining and Congo red staining on mouse tissue pathological sections, it was found that after the use of LYSO-6 to establish the model, lesions occurred in the heart, liver, spleen, kidney, blood vessels, skin and other tissues of the mice, and the cell morphology changed. After the tissues were stained with Congo red, apple green birefringence light was visible under a polarized light microscope, indicating that amyloid deposition occurred in multiple organs of the mice in the model group, proving that a secondary systemic amyloidosis mouse model was successfully established.
[0068] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art may still modify the technical solutions described in the aforementioned embodiments, or make equivalent substitutions for some of the technical features therein; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for establishing a systemic amyloidosis model, characterized in that: First, drugs were used to stimulate mice to produce inflammation, and during this period, amyloid lysozyme LYSO-6 was injected into the tail vein to obtain a systemic amyloidosis model.
2. The method for establishing a systemic amyloidosis model according to claim 1, characterized in that: The method of stimulating inflammation in mice is: administering 0.15-0.25 mL of 1.5-2.5% AgNO3 subcutaneously on the back for 13-15 consecutive days to stimulate inflammation.
3. The method for establishing a systemic amyloidosis model according to claim 1, characterized in that: On days 7-9 and 13-15, 0.05-0.15 mL of amyloidogenic lysozyme LYSO-6 with a final concentration of 0.5-1.5 mg / mL was injected through the tail vein.
4. The method for establishing a systemic amyloidosis model according to claim 1, characterized in that: Mice were selected from 7-week-old male C57BL / 6 mice.
5. The method for establishing a systemic amyloidosis model according to claim 1, characterized in that: Amyloid diseased tissue includes heart tissue, liver tissue, spleen tissue, kidney tissue, blood vessels and skin tissue.
6. The method for establishing a systemic amyloidosis model according to claim 1, characterized in that: The time required to establish the systemic amyloidosis model is 48-52 days.
7. The method for establishing a systemic amyloidosis model according to claim 1, characterized in that: The preparation method of amyloidosis lysozyme LYSO-6 is as follows: S1: Add appropriate amount of egg white lysozyme powder to hydrochloric acid solution with a pH of 2 to a final concentration of 1mM, and let it stand at 4℃ for 8-10h to fully dissolve. After it is completely dissolved, filter it with a 0.22-0.45μm filter membrane; S2: Place the lysozyme incubation solution in a constant temperature oscillator with the oscillator setting conditions at 65±2℃, 50 rpm, incubate continuously for 6 days, and store at 3~5℃.
8. The method for establishing a systemic amyloidosis model according to claim 1, characterized in that: Seven-week-old male C57BL / 6 mice were adaptively raised for one week. Starting from the 8th day, 0.20 mL of 2% AgNO3 was subcutaneously administered to the back for 14 consecutive days to stimulate inflammation. On the 8th and 15th days, 0.10 mL of amyloid lysozyme LYSO-6 with a final concentration of 1 mg / mL was injected once through the tail vein to obtain a systemic amyloidosis model. Mouse tissues were collected on the 50th day.
9. A systemic amyloidosis model obtained by the method according to any one of claims 1 to 8.
10. Use of a systemic amyloidosis model obtained by the method according to any one of claims 1 to 8 in screening drugs for treating or preventing amyloidosis.
Citation Information
Patent Citations
Ocular detection of amyloid proteins
CA2834056A1
Application of <131>I marked SAP for preparing medicine for diagnosing amyloidosis
CN101985045A
Induction method of lysozyme amyloid fiber model
CN110904080A
Application of p-hydroxyphenylpropionic acid in preparation of protein amyloid fibrosis inhibitor
CN116059194A
Construction method of recombinant adeno-associated virus and light chain amyloidosis animal model
CN117603921A
Cited By
Construction method and application of animal model for cardiomyopathy induced by circulating system
CN120391393A
A method for constructing an animal model of cardiomyopathy induced by circulatory system and application thereof
CN120391393B
